Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 146

1.

Sensitivity, but not specificity, of a quantitative immunochemical fecal occult blood test for neoplasia is slightly increased by the use of low-dose aspirin, NSAIDs, and anticoagulants.

Levi Z, Rozen P, Hazazi R, Vilkin A, Waked A, Maoz E, Birkenfeld S, Lieberman N, Klang S, Niv Y.

Am J Gastroenterol. 2009 Apr;104(4):933-8. doi: 10.1038/ajg.2009.14. Epub 2009 Mar 17.

PMID:
19293792
2.

Quantitative colonoscopic evaluation of relative efficiencies of an immunochemical faecal occult blood test and a sensitive guaiac test for detecting significant colorectal neoplasms.

Rozen P, Levi Z, Hazazi R, Waked A, Vilkin A, Maoz E, Birkenfeld S, Niv Y.

Aliment Pharmacol Ther. 2009 Feb 15;29(4):450-7. doi: 10.1111/j.1365-2036.2008.03898.x. Epub 2008 Nov 17.

3.

A quantitative immunochemical fecal occult blood test for colorectal neoplasia.

Levi Z, Rozen P, Hazazi R, Vilkin A, Waked A, Maoz E, Birkenfeld S, Leshno M, Niv Y.

Ann Intern Med. 2007 Feb 20;146(4):244-55.

PMID:
17310048
4.

Identification of colorectal adenomas by a quantitative immunochemical faecal occult blood screening test depends on adenoma characteristics, development threshold used and number of tests performed.

Rozen P, Levi Z, Hazazi R, Waked A, Vilkin A, Maoz E, Birkenfeld S, Leshno M, Niv Y.

Aliment Pharmacol Ther. 2009 Apr 15;29(8):906-17. doi: 10.1111/j.1365-2036.2009.03946.x.

5.

Cumulative evaluation of a quantitative immunochemical fecal occult blood test to determine its optimal clinical use.

Rozen P, Comaneshter D, Levi Z, Hazazi R, Vilkin A, Maoz E, Birkenfeld S, Niv Y.

Cancer. 2010 May 1;116(9):2115-25. doi: 10.1002/cncr.25012.

6.

Can patients at high risk for significant colorectal neoplasms and having normal quantitative faecal occult blood test postpone elective colonoscopy?

Hazazi R, Rozen P, Leshno M, Levi Z, Samuel Z, Waked A, Vilkin A, Maoz E, Birkenfeld S, Niv Y.

Aliment Pharmacol Ther. 2010 Feb 15;31(4):523-33. doi: 10.1111/j.1365-2036.2009.04202.x. Epub 2009 Nov 19.

7.

Performance characteristics and evaluation of an automated-developed and quantitative, immunochemical, fecal occult blood screening test.

Vilkin A, Rozen P, Levi Z, Waked A, Maoz E, Birkenfeld S, Niv Y.

Am J Gastroenterol. 2005 Nov;100(11):2519-25.

PMID:
16279909
8.

Editorial: It's time to make organized colorectal cancer screening convenient and easy for patients.

Levin TR.

Am J Gastroenterol. 2009 Apr;104(4):939-41. doi: 10.1038/ajg.2009.18. Epub 2009 Mar 17.

PMID:
19293790
9.

Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population.

van Rossum LG, van Rijn AF, Laheij RJ, van Oijen MG, Fockens P, van Krieken HH, Verbeek AL, Jansen JB, Dekker E.

Gastroenterology. 2008 Jul;135(1):82-90. doi: 10.1053/j.gastro.2008.03.040. Epub 2008 Mar 25.

PMID:
18482589
10.

Tumor pyruvate kinase isoenzyme type M2 and immunochemical fecal occult blood test: performance in screening for colorectal cancer.

Mulder SA, van Leerdam ME, van Vuuren AJ, Francke J, van Toorenenbergen AW, Kuipers EJ, Ouwendijk RJ.

Eur J Gastroenterol Hepatol. 2007 Oct;19(10):878-82.

PMID:
17873612
11.

Fecal occult blood test in patients on low-dose aspirin, warfarin, clopidogrel, or non-steroidal anti-inflammatory drugs.

Sawhney MS, McDougall H, Nelson DB, Bond JH.

Dig Dis Sci. 2010 Jun;55(6):1637-42. doi: 10.1007/s10620-010-1150-4. Epub 2010 Mar 3.

PMID:
20195757
13.

Screening for familial colorectal cancer with a sensitive immunochemical fecal occult blood test: a pilot study.

Gimeno-García AZ, Quintero E, Nicolás-Pérez D, Hernández-Guerra M, Parra-Blanco A, Jiménez-Sosa A.

Eur J Gastroenterol Hepatol. 2009 Sep;21(9):1062-7. doi: 10.1097/MEG.0b013e3283293797.

PMID:
19307978
14.

[Chemical or immunological tests for the detection of fecal occult blood in colorectal cancer screening?].

Quintero E.

Gastroenterol Hepatol. 2009 Oct;32(8):565-76. doi: 10.1016/j.gastrohep.2009.01.179. Epub 2009 Jul 3. Review. Spanish.

PMID:
19577340
15.

Evaluation of a desk top instrument for the automated development and immunochemical quantification of fecal occult blood.

Rozen P, Waked A, Vilkin A, Levi Z, Niv Y.

Med Sci Monit. 2006 Jun;12(6):MT27-32. Epub 2006 May 29.

PMID:
16733493
16.

Sensitivity of immunochemical fecal occult blood test to small colorectal adenomas.

Morikawa T, Kato J, Yamaji Y, Wada R, Mitsushima T, Sakaguchi K, Shiratori Y.

Am J Gastroenterol. 2007 Oct;102(10):2259-64. Epub 2007 Jul 7.

PMID:
17617203
17.

A comparison of the immunochemical fecal occult blood test and total colonoscopy in the asymptomatic population.

Morikawa T, Kato J, Yamaji Y, Wada R, Mitsushima T, Shiratori Y.

Gastroenterology. 2005 Aug;129(2):422-8.

PMID:
16083699
18.

Comparative evaluation of immunochemical fecal occult blood tests for colorectal adenoma detection.

Hundt S, Haug U, Brenner H.

Ann Intern Med. 2009 Feb 3;150(3):162-9.

PMID:
19189905
19.

Follow-up of patients undergoing both semiquantitated immunochemical fecal occult blood and colonoscopy examinations.

Rozen P, Liphshitz I, Barchana M.

Eur J Cancer Prev. 2012 May;21(3):247-53. doi: 10.1097/CEJ.0b013e32834c9cc6.

PMID:
21955798
20.

Comparison of CT colonography, colonoscopy, sigmoidoscopy and faecal occult blood tests for the detection of advanced adenoma in an average risk population.

Graser A, Stieber P, Nagel D, Schäfer C, Horst D, Becker CR, Nikolaou K, Lottes A, Geisbüsch S, Kramer H, Wagner AC, Diepolder H, Schirra J, Roth HJ, Seidel D, Göke B, Reiser MF, Kolligs FT.

Gut. 2009 Feb;58(2):241-8. doi: 10.1136/gut.2008.156448. Epub 2008 Oct 13.

PMID:
18852257

Supplemental Content

Support Center